Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New injectable HIV combo aims to replace daily pills for heavily treated patients

NCT ID NCT06657885

First seen Jan 17, 2026 · Last updated May 18, 2026 · Updated 22 times

Summary

This study tested a new two-drug injectable treatment for people with HIV who have tried many medications. The goal was to see if a long-acting shot of cabotegravir and lenacapavir could keep the virus under control without daily pills. The study was withdrawn before enrolling any participants, so no results are available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV1 INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU de nantes- Hotel Dieu

    Nantes, France

  • Centre hospitalier François Mitterrand

    Dijon, France

  • Centre hospitalier de Tourcoing

    Tourcoing, France

  • Chu- Nice Archet

    Nice, France

  • Hopital Bichat Claude Bernard

    Paris, 75018, France

  • Hopital Necker

    Paris, 75015, France

  • Hopital Pitié Salpêtrière

    Paris, 75013, France

  • Hopital Saint André

    Bordeaux, France

  • Hopital Saint Antoine

    Paris, 75012, France

  • Hopital raymond Poincaré

    Garches, France

  • Hopiytal Pellegrin

    Bordeaux, France

  • Hôpital Franco-Britannique

    Levallois-Perret, France

Conditions

Explore the condition pages connected to this study.